References
- Jones DS. History in a Crisis — lessons for Covid-19. N Engl J Med. 2020;382:1681–1683.
- Centers for Disease Control and Prevention (CDC). Update: outbreak of severe acute respiratory syndrome–worldwide, 2003. MMWR Morb Mortal Wkly Rep. 2003;52:241–246, 248.
- Zaki AM, van Boheemen S, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med. 2012;367:1814–1820.
- Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727–733.
- Ran L, Chen X, Wang Y, et al. Risk factors of healthcare workers with corona virus disease 2019: a retrospective cohort study in a designated hospital of Wuhan in China. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020. DOI:10.1093/cid/ciaa287
- Bahl P, Doolan C, de Silva C, et al. Airborne or droplet precautions for health workers treating coronavirus disease 2019? J Infect Dis. 2020. DOI:10.1093/infdis/jiaa189
- Gagneux-Brunon A, Lucht F, Launay O, et al. Vaccines for healthcare-associated infections: present, future, and expectations. Expert Rev Vaccines. 2018;17(5):421–433.
- Liu S, Chan T-C, Chu Y-T, et al. Comparative epidemiology of human infections with middle east respiratory syndrome and severe acute respiratory syndrome coronaviruses among healthcare personnel. PLoS One. 2016;11(3):e0149988.
- The Lancet. COVID-19: protecting health-care workers. Lancet. 2020;395:922.
- McMichael TM, Currie DW, Clark S, et al. Epidemiology of Covid-19 in a long-term care facility in king county, Washington. N Engl J Med. [Internet]. 2020;382(21):2005–2011. [cited 2020 Apr 22]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121761/
- Cook TM. Personal protective equipment during the coronavirus disease (COVID) 2019 pandemic – a narrative review. Anaesthesia. 2020. DOI:10.1111/anae.15071
- WHO | Severe acute respiratory syndrome (SARS) [Internet]. World Health Organization [WHO]; [ cited 2020 May 14]. Available from: https://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/
- Stadler K, Masignani V, Eickmann M, et al. SARS — beginning to understand a new virus. Nat Rev Microbiol. 2003;1:209–218.
- Lee N, Hui D, Wu A, et al. A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med. 2003;348(20):1986–1994.
- Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Inter Med. 2003;139:715.
- WHO | Summary of probable SARS cases with onset of illness from1 November 2002 to 31 July 2003 [Internet]. World Health Organization [WHO]; [ cited 2020 Apr 22]. Available from: http://www.who.int/csr/sars/country/table2004_04_21/en/
- Booth CM, et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater toronto area. JAMA. 2003;289(21):2801–2809.
- Ip M, Chan PKS, Lee N, et al. Seroprevalence of antibody to Severe Acute Respiratory Syndrome (SARS)–associated coronavirus among health care workers in SARS and non-SARS medical wards. Clin Infect Dis. 2004;38:e116–e118.
- Vu TH, Cabau J-F, Nguyen NT, et al. SARS in Northern Vietnam. N Engl J Med. 2003;348(20):2035.
- Liang W, Zhu Z, Guo J, et al. Severe acute respiratory syndrome, Beijing, 2003. Emerg Infect Dis. 2004;10(1):25–31.
- Wang J, Feng H, Liu D, et al. Epidemiological characteristics of severe acute respiratory syndrome in Tianjin and the assessment of effectiveness on measures of control. Zhonghua Liu Xing Bing Xue Za Zhi Zhonghua Liuxingbingxue Zazhi.2003;24:565–569.
- Dwosh HA, Hong HHL, Austgarden D, et al. Identification and containment of an outbreak of SARS in a community hospital.CMAJ Can Med Assoc J J Assoc Medicale Can. 2003;168:1415–1420.
- Ofner M, Lem M, Sarwal S, et al. Cluster of severe acute respiratory syndrome cases among protected health care workers-Toronto, April 2003.Can Commun Dis Rep Releve Mal Transm Au Can. 2003;29:93–97.
- Chen K-T, Twu S-J, Chang H-L, et al. SARS in Taiwan: an overview and lessons learned. Int J Infect Dis. 2005;9:77–85.
- Leong H-N, Chan K-P, Oon LLE, et al. Clinical and laboratory findings of SARS in Singapore. Ann Acad Med Singapore. 2006;35:332–339.
- Ofner-Agostini M, Wallington T, Henry B, et al. Investigation of the second wave (phase 2) of severe acute respiratory syndrome (SARS) in Toronto, Canada. What happened? Can Commun Dis Rep Releve Mal Transm Au Can. 2008;34:1–11.
- de Wit E, van Doremalen N, Falzarano D, et al. SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016;14:523–534.
- Hijawi B, Abdallat M, Sayaydeh A. et al. Novel coronavirus infections in Jordan, April 2012: epidemiological findings from a retrospective investigation. East Mediterr Health J Rev Sante Mediterr Orient Al-Majallah Al-Sihhiyah Li-Sharq Al-Mutawassit. 2013;19(Suppl 1):S12–18.
- WHO. EMRO | MERS situation update, January 2020 | MERS-CoV | Epidemic and pandemic diseases [Internet]. [ cited 2020 Apr 27]. Available from: http://www.emro.who.int/pandemic-epidemic-diseases/mers-cov/mers-situation-update-january-2020.html
- Hui DS, Azhar EI, Kim Y-J, et al. Middle East respiratory syndrome coronavirus: risk factors and determinants of primary, household, and nosocomial transmission. Lancet Infect Dis. 2018;18(8):e217–e227.
- Balkhy HH, Alenazi TH, Alshamrani MM, et al. Description of a hospital outbreak of Middle East respiratory syndrome in a large tertiary care hospital in Saudi Arabia. Infect Control Hosp Epidemiol. 2016;37:1147–1155.
- Elkholy AA, Grant R, Assiri A, et al. MERS-CoV infection among healthcare workers and risk factors for death: retrospective analysis of all laboratory-confirmed cases reported to WHO from 2012 to 2 June 2018. J Infect Public Health. 2020;13:418–422.
- Cho SY, Kang J-M, Ha YE, et al. MERS-CoV outbreak following a single patient exposure in an emergency room in South Korea: an epidemiological outbreak study. Lancet. 2016;388(10048):994–1001.
- Hastings DL, Tokars JI, Abdel Aziz IZAM, et al. Outbreak of Middle East respiratory syndrome at tertiary care hospital, Jeddah, Saudi Arabia, 2014. Emerg Infect Dis. 2016;22(5):794–801.
- Choi S, Jung E, Choi BY, et al. High reproduction number of Middle East respiratory syndrome coronavirus in nosocomial outbreaks: mathematical modelling in Saudi Arabia and South Korea. J Hosp Infect. 2018;99:162–168.
- Alfaraj SH, Al-Tawfiq JA, Altuwaijri TA, et al. Middle East respiratory syndrome coronavirus transmission among health care workers: implication for infection control. Am J Infect Control. 2018;46(2):165–168.
- Assiri A, McGeer A, Perl TM, et al. Hospital outbreak of middle east respiratory syndrome coronavirus. N Engl J Med. 2013;369(5):407–416.
- Arabi YM, Arifi AA, Balkhy HH, et al. Clinical course and outcomes of critically ill patients with middle east respiratory syndrome coronavirus infection. Ann Intern Med. 2014;160(6):389–397.
- Noorwali AA, Turkistani AM, Asiri SI, et al. Descriptive epidemiology and characteristics of confirmed cases of Middle East respiratory syndrome coronavirus infection in the Makkah Region of Saudi Arabia, March to June 2014. Ann Saudi Med. 2015;35:203–209.
- Assiri A, Abedi GR, Saeed AAB, et al. Multifacility outbreak of Middle East respiratory syndrome in Taif, Saudi Arabia. Emerg Infect Dis. 2016;22:32–40.
- Hunter JC, Nguyen D, Aden B, et al. Transmission of Middle East respiratory syndrome coronavirus infections in healthcare settings, Abu Dhabi. Emerg Infect Dis. 2016;22:647–656.
- Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020;382:1199–1207.
- Ma Y, Diao B, Lv X, et al. 2019 novel coronavirus disease in hemodialysis (HD) patients: report from one HD center in Wuhan, China. medRxiv. 2020;2020(2):24.20027201.
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061.
- Livingston E, Bucher K. COVID-19 in Italy. JAMA. 2019;2020(323):1335.
- Gao W, Sanna M, Wen CP. Geo temporal distribution of 1,688 Chinese healthcare workers infected with COVID-19 in severe conditions, a secondary data analysis. medRxiv. 2020;2020(3):19.20032532.
- Roxby AC, Greninger AL, Hatfield KM, et al. Detection of SARS-CoV-2 among residents and staff members of an independent and assisted living community for older adults - Seattle, Washington, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(14):416–418.
- Wang X, Zhou Q, He Y, et al. Nosocomial outbreak of COVID-19 pneumonia in Wuhan, China. Eur Respir J. [Internet]. 2020;69(6):2000544. [cited 2020 Aug 10]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236818/
- COVID-19 Map [Internet]. Johns Hopkins coronavirus resour. Cent. [ cited 2020 Apr 28]. Available from: https://coronavirus.jhu.edu/map.html
- Cook T, Kursumovic E, Lennane S. Exclusive: deaths of NHS staff from covid-19 analysed [Internet]. Health Serv J. 2020 April [cited 2020 Apr 27]. Available from: https://www.hsj.co.uk/exclusive-deaths-of-nhs-staff-from-covid-19-analysed/7027471.article
- Heinzerling A, Stuckey MJ, Scheuer T, et al. Transmission of COVID-19 to health care personnel during exposures to a hospitalized patient - Solano County, California, February 2020. MMWR Morb Mortal Wkly Rep. 2020;69:472–476.
- Hunter E, Price DA, Murphy E, et al. First experience of COVID-19 screening of health-care workers in England. Lancet. 2020;395(10234):e77–e78.
- Schwierzeck V, König JC, Kühn J, et al. First reported nosocomial outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a pediatric dialysis unit. Clin Infect Dis Off Publ Infect Dis Soc Am. 2020. DOI: 10.1093/cid/ciaa491
- Arons MM, Hatfield KM, Reddy SC, et al. Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility. N Engl J Med. 2020. DOI:10.1056/NEJMoa2008457
- Mizumoto K, Kagaya K, Zarebski A, et al. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the diamond princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. 2020;25(10):2000180.
- Baggett TP, Keyes H, Sporn N, et al. Prevalence of SARS-CoV-2 infection in residents of a large homeless Shelter in Boston. JAMA. [Internet]. 2020;323(21):2191. [cited 2020 Apr 28]. Available from: https://jamanetwork.com/journals/jama/fullarticle/2765378
- He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19. Nat Med. 2020 May;26(5):672-675.
- Comar M, Brumat M, Concas MP, et al. COVID-19 experience: first Italian survey on healthcare staff members from a mother-child research hospital using combined molecular and rapid immunoassays test. medRxiv. 2020;2020(4):19.20071563.
- Burrer SL, de Perio MA, Hughes MM, CDC COVID-19 Response Team. Characteristics of health care personnel with COVID-19 - united States, February 12-April 9, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):477–481.
- Keeley AJ, Evans C, Colton H, et al. Roll-out of SARS-CoV-2 testing for healthcare workers at a large NHS foundation trust in the United Kingdom, March 2020. Eurosurveillance 2020;25(14):2000433.
- Reusken CB, Buiting A, Bleeker-Rovers C, et al.Rapid assessment of regional SARS-CoV-2 community transmission through a convenience sample of healthcare workers, the Netherlands, March 2020.Eurosurveillance [Internet]. 2020;25(12). [cited 2020 Apr 22]. DOI:10.2807/1560-7917.ES.2020.25.12.2000334
- Garcia-Basteiro AL, Moncunill G, Tortajada M, et al. Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020;11:3500.
- Schmidt SB, Grüter L, Boltzmann M, et al. Prevalence of serum IgG antibodies against SARS-CoV-2 among clinic staff. PLoS One. 2020;15(6):e0235417.
- Moscola J, Sembajwe G, Jarrett M, et al. Prevalence of SARS-CoV-2 antibodies in health care personnel in the New York city area. JAMA. [Internet]. 2020;324(9):893. [cited 2020 Aug 10]. Available from: http://jamanetwork.com/journals/jama/fullarticle/2769322
- Steensels D, Oris E, Coninx L, et al. Hospital-wide SARS-CoV-2 antibody screening in 3056 staff in a tertiary center in Belgium. JAMA. 2020;324(2):195–197.
- Recensement national des cas de COVID-19 chez les professionnels en établissements de santé [Internet]; [ cited 2020 Aug 17]. Available from: /etudes-et-enquetes/recensement-national-des-cas-de-covid-19-chez-les-professionnels-en-etablissements-de-sante
- Riccardo F, Ajelli M, Andrianou X, et al. Epidemiological characteristics of COVID-19 cases in Italy and estimates of the reproductive numbers one month into the epidemic. medRxiv. 2020;2020(4):08.20056861.
- Wang N, Shang J, Jiang S, et al. Subunit vaccines against emerging pathogenic human coronaviruses. Front Microbiol. [Internet]. 2020;11. [cited 2020 Apr 28]. Available from: https://www.frontiersin.org/articles/10.3389/fmicb.2020.00298/full
- Callaway E. The race for coronavirus vaccines: a graphical guide. Nature. 2020;580(7805):576–577.
- Martin JE, Louder MK, Holman LA, et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine. 2008;26:6338–6343.
- Lin J-T, Zhang J-S, Su N, et al. Safety and immunogenicity from a phase I trial of inactivated severe acute respiratory syndrome coronavirus vaccine. Antivir Ther. 2007;12:1107–1113.
- Modjarrad K, Roberts CC, Mills KT, et al. Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. Lancet Infect Dis. 2019;19(9):1013–1022.
- Koch T, Dahlke C, Fathi A, et al. Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. Lancet Infect Dis. 2020. DOI:10.1016/S1473-3099(20)30248-6
- Study of Safety and Immunogenicity of BVRS-GamVac - Full Text View - ClinicalTrials.gov [Internet]. [ cited 2020 Apr 29]. Available from: https://clinicaltrials.gov/ct2/show/NCT04130594
- Folegatti PM, Bittaye M, Flaxman A, et al. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial. Lancet Infect Dis. [Internet]. 2020;20(7):816–826. [cited 2020 Apr 29]. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7172901/
- Draft landscape of COVID-19 candidate vaccines [Internet]. [ cited 2020 Aug 10]. Available from: https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines
- Le TT, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Rev Drug Discov. [Internet]. 2020 [cited 2020 Apr 12]. DOI:10.1038/d41573-020-00151-8
- Search of: vaccine | SARS-CoV2 - List Results - ClinicalTrials.gov [Internet]. [ cited 2020 Apr 29]. Available from: https://clinicaltrials.gov/ct2/results?cond=SARS-CoV+2&term=vaccine&cntry=&state=&city=&dist=
- Calina D, Docea AO, Petrakis D, et al. Towards effective COVID‑19 vaccines: updates, perspectives and challenges (Review). Int J Mol Med. 2020;46(1):3–16.
- Zhu F-C, Li Y-H, Guan X-H, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020;395(10240):1845–1854.
- Zhu F-C, Guan X-H, Li Y-H, et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. [Internet]. 2020 [cited 2020 Aug 10]. Available from: https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31605-6/abstract
- Folegatti PM, Ewer KJ, Aley PK, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. [Internet]. 2020;396(10249):467–478. [cited 2020 Aug 10]. Available from: http://www.sciencedirect.com/science/article/pii/S0140673620316044
- Jackson LA, Anderson EJ, Rouphael NG, et al. An mRNA vaccine against SARS-CoV-2 — preliminary report. N Engl J Med 2020 Jul 14;NEJMoa2022483.
- Xia S, Duan K, Zhang Y, et al. Effect of an inactivated vaccine against SARS-CoV-2 on safety and immunogenicity outcomes: interim analysis of 2 randomized clinical trials. JAMA. [Internet]. 2020;324(10):951. [cited 2020 Aug 17]. Available from: http://jamanetwork.com/journals/jama/fullarticle/2769612
- Ozdemir C, Kucuksezer UC, Tamay ZU, Is BCG vaccination effecting the spread and severity of COVID-19? Allergy. [Internet]. n/a [cited 2020 Apr 28]. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1111/all.14344
- Yitbarek K, Abraham G, Girma T, et al. The effect of Bacillus Calmette–Guérin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: implications for the COVID-19 pandemic. Vaccine. [Internet]. 2020;38(41):6374–6380. [cited 2020 Aug 11]. Available from: http://www.sciencedirect.com/science/article/pii/S0264410X20310495
- Hamiel U, Kozer E, Youngster I. SARS-CoV-2 rates in BCG-vaccinated and unvaccinated young adults. JAMA [Internet]. 2020;323(22):2340. [cited 2020 May 14]. Available from: https://jamanetwork.com/journals/jama/fullarticle/2766182
- Search of: BCG | COVID-19 - List Results - ClinicalTrials.gov [Internet]; [ cited 2020 Apr 28]. Available from: https://clinicaltrials.gov/ct2/results?cond=COVID-19&term=BCG&cntry=&state=&city=&dist=
- Franklin R, Young A, Neumann B, et al. Homologous protein domains in SARS-CoV-2 and measles, mumps and rubella viruses: preliminary evidence that MMR vaccine might provide protection against COVID-19. medRxiv. 2020;2020(4):10.20053207.
- Measles Vaccine in HCW - Full Text View - ClinicalTrials.gov [Internet]; [ cited 2020 Apr 28]. Available from: https://clinicaltrials.gov/ct2/show/NCT04357028
- Nitulescu GM, Paunescu H, Moschos SA, et al. Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: mechanistic insights into current COVID‑19 therapies (Review). Int J Mol Med. 2020;46(2):467–488.
- Park SY, Lee JS, Son JS, et al. Post-exposure prophylaxis for Middle East respiratory syndrome in healthcare workers. J Hosp Infect. 2019;101(1):42–46.
- Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020;11(1):1–14.
- Sanders JM, Monogue ML, Jodlowski TZ, et al. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. [Internet]. 2020 [cited 2020 May 5]. DOI:10.1001/jama.2020.6019
- Rosenke K, Jarvis MA, Feldmann F, et al. Hydroxychloroquine proves ineffective in hamsters and macaques infected with SARS-CoV-2. bioRxiv. 2020;2020(6):10.145144.
- Maisonnasse P, Guedj J, Contreras V, et al. Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates. Nature. 2020;1–8.
- Boulware DR, Pullen MF, Bangdiwala AS, et al. A randomized trial of hydroxychloroquine as postexposure prophylaxis for Covid-19. N Engl J Med 2020 Aug 6;383(6):517-525.
- Chatterjee P, Anand T, Singh KJ, et al. Healthcare workers & SARS-CoV-2 infection in India: A case-control investigation in the time of COVID-19. Indian J Med Res. 2020;151(5):459–467.
- Mehra MR, Desai SS, Ruschitzka F, et al. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. Lancet. [Internet]. 2020 [cited 2020 May 27]. Available from: http://www.sciencedirect.com/science/article/pii/S0140673620311806
- No clinical benefit from use of lopinavir-ritonavir in hospitalised COVID-19 patients studied in RECOVERY. Available from: https://www.recoverytrial.net/news/no-clinical-benefit-from-use-of-lopinavir-ritonavir-in-hospitalised-covid-19-patients-studied-in-recovery
- Rossignol J-F. Nitazoxanide: a first-in-class broad-spectrum antiviral agent. Antiviral Res. 2014;110:94–103.
- Akerström S, Gunalan V, Keng CT, et al. Dual effect of nitric oxide on SARS-CoV replication: viral RNA production and palmitoylation of the S protein are affected. Virology. 2009;395(1):1–9.
- Leiva-Juarez MM, Kirkpatrick CT, Gilbert BE, et al. Combined aerosolized Toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir. Eur J Pharmacol. 2018;818:191–197.
- Lurie N, Saville M, Hatchett R, et al. Developing Covid-19 vaccines at pandemic speed. N Engl J Med 2020 May 21;382(21):1969-1973.
- Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020. DOI:10.1038/s41586-020-2538-8
- Rivett L, Sridhar S, Sparkes D, et al. Screening of healthcare workers for SARS-CoV-2 highlights the role of asymptomatic carriage in COVID-19 transmission. eLife. 2020 May 11;9:e58728.
- Stratégie de vaccination contre le COVID 19 - Anticipation des scénarios possibles de vaccination et recommandations préliminaires sur les populations cibles [Internet]. Haute Aut Santé; [ cited 2020 Aug 10]. Available from. https://www.has-sante.fr/jcms/p_3197106/fr/strategie-de-vaccination-contre-le-covid-19-anticipation-des-scenarios-possibles-de-vaccination-et-recommandations-preliminaires-sur-les-populations-cibles
- Gagneux-Brunon A, Pelissier C, Gagnaire J, et al. SARS-CoV-2 infection: advocacy for training and social distancing in healthcare settings. J Hosp Infect. [Internet]. 2020 [cited 2020 Aug 10]. Available from: https://www.journalofhospitalinfection.com/article/S0195-6701(20)30379-0/abstract
- Ten health issues WHO will tackle this year [Internet]. [ cited 2020 Apr 3]. Available from: https://www.who.int/news-room/feature-stories/ten-threats-to-global-health-in-2019
- Killian M, Detoc M, Berthelot P, et al. Vaccine hesitancy among general practitioners: evaluation and comparison of their immunisation practice for themselves, their patients and their children. Eur J Clin Microbiol Infect Dis. 2016;35:1837–1843.
- Agrinier N, Le Maréchal M, Fressard L, et al. Discrepancies between general practitioners‘ vaccination recommendations for their patients and practices for their children. Clin Microbiol Infect. 2017;23(5):311–317.
- Wilson R, Zaytseva A, Bocquier A, et al. Vaccine hesitancy and self-vaccination behaviors among nurses in southeastern France. Vaccine. 2020;38(5):1144–1151.
- Peretti-Watel P, Seror V, Cortaredona S, et al. A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation. Lancet Infect Dis. 2020;20(7):769–770.
- Dodd RH, Cvejic E, Bonner C, et al. Willingness to vaccinate against COVID-19 in Australia. Lancet Infect Dis. [Internet]. 2020 [cited 2020 Aug 10]. DOI:10.1016/S1473-3099(20)30559-4
- Salje H, Kiem CT, Lefrancq N, et al. Estimating the burden of SARS-CoV-2 in France. Science. [Internet]. 2020;369(6500):208–211. [cited 2020 May 14]. Available from: https://science.sciencemag.org/content/early/2020/05/12/science.abc3517
- Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals. Cell. [Internet]. 2020;181(7):1489–1501.e15. [cited 2020 May 22]. Available from: http://www.sciencedirect.com/science/article/pii/S0092867420306103
- Le Bert N, Tan AT, Kunasegaran K, et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature. 2020;1–10.
- Mateus J, Grifoni A, Tarke A, et al. Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans. Science. 2020. DOI:10.1126/science.abd3871
- Park S-J, Yu K-M, Kim Y-I, et al. Antiviral efficacies of FDA-approved drugs against SARS-CoV-2 infection in ferrets. mBio. 2020;11.
- Kissler SM, Tedijanto C, Goldstein E, et al. Projecting the transmission dynamics of SARS-CoV-2 through the postpandemic period. Science. [Internet]. 2020;368(6493):860–868. [cited 2020 May 14]. Available from: http://science.sciencemag.org/content/early/2020/05/11/science.abb5793